Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease

被引:6
|
作者
Fan, Hong [1 ,2 ,3 ,4 ]
Li, Lili [1 ,2 ,5 ]
Liu, Zhenqiu [4 ,6 ,7 ,8 ]
Zhang, Pengyan [1 ,2 ,3 ,4 ]
Wu, Sheng [1 ,2 ,3 ]
Han, Xinyu [1 ,2 ,3 ]
Chen, Xingdong [3 ,4 ,6 ,7 ,8 ]
Suo, Chen [1 ,2 ,3 ,4 ]
Cao, Liou [5 ]
Zhang, Tiejun [1 ,2 ,3 ,4 ]
机构
[1] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200032, Peoples R China
[2] Fudan Univ, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Inst Infect Dis & Biosecur, Sch Publ Hlth, Shanghai, Peoples R China
[4] Fudan Univ, Taizhou Inst Hlth Sci, Taizhou, Peoples R China
[5] Affiliated Shanghai Univ Med & Hlth Sci, Jiading Dist Cent Hosp, Shanghai 200032, Peoples R China
[6] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200438, Peoples R China
[7] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, Shanghai 200438, Peoples R China
[8] Fudan Univ, Human Phenome Inst, 825 Zhangheng Rd, Shanghai, Peoples R China
关键词
Fatty liver disease; MAFLD; Fibrosis; Low-normal thyroid function; Subclinical hypothyroidism; NONALCOHOLIC STEATOHEPATITIS; SUBCLINICAL HYPOTHYROIDISM; EUTHYROID SUBJECTS; NATIONAL-HEALTH; HORMONES; NAFLD;
D O I
10.1186/s12876-022-02612-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims Observational studies showed that low thyroid function may perturb liver function. We aimed to evaluate the association of low thyroid function with both metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced hepatic fibrosis.Methods Participants who underwent abdominal ultrasonography and thyroid function test in a Chinese hospital from 2015 to 2021were enrolled. Fibrosis-4 index (FIB-4) > 2.67 and/or non-alcoholic fatty liver disease fibrosis score (NFS) > 0.676 were used to define advanced fibrosis. Descriptive analyses were performed to characterize the epidemiology of MAFLD according to levels of thyroid-stimulating hormone (TSH). The logistic regression model was applied to estimate the association of low thyroid function with MAFLD and advanced fibrosis.Results A total of 19,946 participants (52.78% males, mean age: 47.31 years, 27.55% MAFLD) were included, among which 14,789 were strict-normal thyroid function, 4,328 were low-normal thyroid function, 829 were subclinical hypothyroidism. TSH levels were significantly higher in MAFLD patients with a FIB-4 > 2.67 and /or NFS > 0.676 than their counterparts. The logistic regression model adjusted for age and sex showed that low-normal thyroid function increased the risk of MAFLD (odds ratio [OR] = 1.09; 95% confidence interval [CI] 1.01-1.18). Multivariable regression model adjusted for age, sex, body mass index, type 2 diabetes, and hypertension showed low-normal thyroid function increased the risk of advanced fibrosis in patients with MAFLD (FIB-4 > 2.67: OR = 1.41, 95% CI 1.02-1.93; NFS > 0.676: OR = 1.72, 95% CI 1.08-2.72).Conclusion Elevated TSH concentrations are associated with advanced hepatic fibrosis, even in the euthyroid state.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
    Zheng, Haixiang
    Sechi, Leonardo Antonio
    Navarese, Eliano Pio
    Casu, Gavino
    Vidili, Gianpaolo
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [22] Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?
    Feng, Gong
    Byrne, Christopher D.
    Targher, Giovanni
    Wang, Fudi
    Zheng, Ming-Hua
    LIVER INTERNATIONAL, 2022, 42 (07) : 1496 - 1502
  • [23] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi, Yiwen
    Fan, Jiangao
    CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1009 - 1018
  • [24] Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
    Fouad, Yasser
    Alboraie, Mohamed
    Shiha, Gamal
    HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 827 - 833
  • [25] Body Composition Analysis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
    Onishi, Saori
    Fukuda, Akira
    Matsui, Masahiro
    Ushiro, Kosuke
    Nishikawa, Tomohiro
    Asai, Akira
    Kim, Soo Ki
    Nishikawa, Hiroki
    NUTRIENTS, 2023, 15 (18)
  • [26] The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
    Barrera, Francisco
    Uribe, Javier
    Olvares, Nixa
    Huerta, Paula
    Cabrera, Daniel
    Romero-Gomez, Manuel
    ANNALS OF HEPATOLOGY, 2024, 29 (04)
  • [27] Diabetes and metabolic dysfunction-associated fatty liver disease
    Davis, Timothy M. E.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 123
  • [28] Advanced Liver Fibrosis Impairs Cardiorespiratory Fitness in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Sogbe, Miguel
    Hummer, Breianna
    Stine, Jonathan G.
    Lizaola-Mayo, Blanca
    Forman, Daniel E.
    Vargas, Hugo E.
    Duarte-Rojo, Andres
    DIGESTIVE DISEASES AND SCIENCES, 2025, : 1530 - 1539
  • [29] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [30] Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implications
    Hu, Shuwei
    Ai, Yingjie
    Hu, Chencheng
    Bawa, Fathima N. Cassim
    Xu, Yanyong
    GENES & DISEASES, 2025, 12 (03)